Decorative
Decorative
Decorative Decorative

Management Team

Punit Dhillon

Chief Executive Officer and Chairman

Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Kaitlyn Arsenault

Chief Financial Officer

Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors. Prior to her appointment as CFO of Skye, she served as an independent consultant for emerging public and private companies, including Skye for the past six years, providing expertise and addressing complex issues related to SEC reporting, technical accounting, stock-based compensation, and revenue recognition, among other subjects. She also served as Assurance Manager in Friedman LLP's SEC practice, gaining public and private audit engagement experience across multiple industries. Ms. Arsenault received her Bachelor of Science degree in accounting from Ramapo College of New Jersey and is a Certified Public Accountant.

Tu Diep, MSc

Chief Development Officer

Mr. Tu Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience.

Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc. (now Sophiris Bio Inc.), a company developing a highly targeted, minimally invasive treatment for benign prostatic hyperplasia and prostate cancer. While at Protox, Mr. Diep held several positions with increasing responsibility, where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. Prior to leaving Protox, he was integrally involved in solidifying a $75 million regional partnership with a Japanese pharmaceutical company and securing a $35 million investment from the private equity firm Warburg Pincus.

In 2011, Mr. Diep joined OncoSec Medical Inc. as a founding employee. He led the development and initiation of the Company's lead program, tavokinogene telsaplasmid (TAVO), an intratumoral gene therapy using DNA plasmid-encoding interleukin-12. As a key member of OncoSec's executive management team, he spearheaded a key clinical collaboration with Merck to evaluate the combination of TAVO plus pembrolizumab, Merck's leading anti-PD-1 antibody for the treatment of metastatic melanoma.

Following OncoSec, Mr. Diep held positions as VP, Strategic Operations for a global cannabis investment company. He was Director, Business Process for a private next-generation sequencing start-up, Element Biosciences. Mr. Diep holds a Master of Science in physiology from the University of Toronto.